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Abstract: Treatment options for Crohn’s disease have evolved beyond the early goals of 
induction and remission and are now more focused on preventing complications by altering 
the natural history of the disease. The advent of biologic therapies has revolutionized the 
management of Crohn’s disease. Specifically, antibodies to tumor necrosis factor alpha 
induce rapid mucosal healing. This translates into improved patient outcomes. However, 
many patients will fail these and other therapies. Natalizumab is a new biologic agent that has 
been approved for the treatment of moderately to severely active Crohn’s disease in patients 
who have failed or are intolerant to immunosuppressants and/or tumor necrosis factor inhibi-
tors. It is a selective adhesion molecule inhibitor to alpha-4 integrin resulting in inhibition of 
the migration of inflammatory cells across the endothelium. This unique mechanism of action 
has been shown to be effective in the treatment of Crohn’s disease, making it an important 
option for otherwise refractory patients. Its use has been limited to these refractory patients 
because of concerns about the development of complications, especially progressive multifocal 
leukoencephalopathy. In this review, evidence-based data on the indications, efficacy and 
safety of natalizumab will be presented and its role in the management of patients with Crohn’s 
disease will be defined.
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Introduction
Crohn’s disease is a heterogeneous chronic inflammatory disease of the gastrointestinal 
tract defined based on endoscopic, histological and radiographic criteria. It can 
manifest as focal or patchy inflammation confined to the bowel wall or result in 
complications such as fistula leading to abscess, or stricture leading to chronic 
intermittent bowel obstruction. Like many other chronic diseases, Crohn’s disease 
has no definitive cure and requires approaches to induce and maintain remission, 
improve quality of life and prevent complications that may occur in the long or 
short term, either related to medication use or directly as a result of the disease.1 
Current cost of medical and surgical therapy is estimated at US$2 billion 
annually.2,3
Selection of therapy is based on disease location, behavior and severity.4 Biological 
therapies especially inhibitors of tumor necrosis factor have revolutionized the 
management of Crohn’s disease. Natalizumab is the first non-anti-TNF alpha biological 
agent approved for the treatment of Crohn’s disease with a unique mechanism of 
action. It will be the focus of this review.Therapeutics and Clinical Risk Management 2009:5 936
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Disease classification and behavior
Patients with Crohn’s disease are classified based on the 
Montreal classification (Table 1) which includes of 
age at diagnosis, disease location and behavior.5 This 
classification has important implications for prognosis and 
therapy. Response rates to medical therapy are different 
based on disease location or behavior, with some medica-
tions effective only for disease confined to the lining of the 
bowel (non-stricturing, non-penetrating) whereas others 
are more effective for penetrating disease.1 Medical therapy 
is ineffective for stricturing disease which leads to chronic 
scarring that may result in bowel obstruction requiring 
surgery. Crohn’s disease behavior may change with time 
with the progression of disease confined to the bowel 
wall to stricturing or penetrating (fistulizing) disease. 
Perianal manifestations are unique to Crohn’s disease 
and may precede the onset of actual bowel symptoms.6 
Gastric and duodenal manifestations are rare but increas-
ingly being recognized. Extra-intestinal manifestations 
include spondylarthritis, peripheral arthritis, cutaneous 
manifestations (erythema nodosum, pyoderma gangreno-
sum), ocular manifestations (uveitis, episcleritis), primary 
sclerosing cholangitis and hypercoagulability. Long dura-
tion of disease can be complicated by gastrointestinal 
malignancy.7,8
Risk factors for predicting early development of severe 
Crohn’s disease include presence of perianal disease, need 
for corticosteroids to treat first flare up and ileo- colonic 
location.9 Age of onset less than 40 is not a good predictor 
for early development of severe disease. Stricturing behavior 
and weight loss greater than 5 kg at diagnosis were indepen-
dently associated with early development of severe disease.9 
However, predictive models remain imperfect due to the 
complex heterogeneity of this disease.
Therapeutic approach 
to Crohn’s disease
Treatment options for Crohn’s disease are individualized to 
disease location, behavior and previous medication use. The 
goals of therapy are to induce and maintain remission and also 
improve the natural history of the disease and avoid surgery.1 
Corticosteroids while effective in inducing remission are not 
effective for remission maintenance and their benefit is only 
among patients with non-stricturing non-penetrating disease. 
They have significant short and long-term side effects and pro-
longed use should be avoided. Immune suppressants including 
azathioprine, 6-mercaptopurine and methotrexate typically 
take weeks or months to become effective and are not used 
for induction of remission but for remission maintenance.4 
Inhibitors of tumor necrosis factor (TNF) alpha (infliximab, 
adalimumab and certolizumab) are biologic agents that are 
effective for rapid induction of remission and maintenance of 
remission among patients with non-stricturing non-penetrating 
disease or penetrating disease. Mesalamine agents, while 
useful in ulcerative colitis, are generally ineffective in Crohn’s 
disease except in some cases of Crohn’s colitis. Antibiotics, 
especially metronidazole, are effective in decreasing drain-
age of fistula and are helpful in the management of Crohn’s 
disease but are not usually given as monotherapy.10 Surgery 
is indicated for disease not responding to medical treatment, 
obstruction secondary to stricturing disease, suppurative 
complications and histologic dysplasia or malignancy.
Current therapy for Crohn’s disease has moved beyond 
the goal of induction and remission and now focuses on 
preventing complications. This “top down” approach 
which involves early introduction of immune modulators 
and biological agents is gaining popularity.11 Inhibitors 
of TNF induce rapid and profound endoscopic healing of 
mucosal lesions, which translates to improved quality of life, 
avoidance of hospitalization and surgery and prevention long 
term complications.12
Unfortunately, as with other therapies a significant 
number of patients are unresponsive, lose response or develop 
intolerance to these medications. For patients who initially 
respond, on average 37% will lose response or a rate of 13% 
per patient-year of treatment.13 These calculations were based 
on studies with up to a year of follow-up. Recent data from 
Belgium have been more encouraging, with nearly two-
thirds of patients maintaining benefit after nearly 5 years 
of follow-up.14 Improved sustained response was likely due 
Table 1 The Montreal classification of Crohn’s disease5
Age at diagnosis (A)  A1 below 16 years
A2 between 17 and 40 years
A3 above 40 years
Location (L)  L1 ileal
L2 colonic
L3 ileocolonic
L4 isolated upper diseasea
Behavior (B)  B1 non-stricturing non-penetrating
B2 stricturing
B3 penetrating
P perianal disease modifierb
Notes: aL4 is a modifier that can be added to L1–L3 when concomitant upper disease 
is present. b“P” is added to B1–B3 when concomitant perianal disease is present.Therapeutics and Clinical Risk Management 2009:5 937
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to dose escalation of infliximab or shortening of the dosing 
interval. However one-third of patients still lost response. 
Many patients who respond to infliximab will need a higher 
dose, a more frequent dosing schedule or both, to maintain 
response. Most of these patients will demonstrate clinical 
response but a third of these will require alternative therapy. 
This proportion may increase as patients are treated for longer 
periods with these agents. Patients who have lost response 
to one agent may respond to a second TNF antagonist. 
Among patients who had failed infliximab, 52% responded 
to adalimumab but remission rates were only 20%.15 These 
patients who fail anti-TNF therapies may potentially benefit 
from natalizumab therapy.
Natalizumab mechanism of action
Alpha-4 integrin is a selective adhesion molecule that 
facilitates adhesion and subsequent leukocyte migration 
into areas of inflammation. Natalizumab (Tysabri®; Elan) 
is a recombinant, humanized, IgG4 monoclonal antibody to 
alpha-4 integrin.16 Inhibition of integrins has been proven 
from animal studies to help in mucosal healing and reduce 
inflammation.
Leukocyte adhesion in endothelial cells is a multi-
step process that involves chemokine receptors and active 
integrins. Firm adhesion is the last step before leukocyte 
diapedesis through endothelial pores into the lamina propria 
of inflamed tissue. Natalizumab blocks both alpha-4 B1 
integrin (VCAM 1) and alpha-4 B7 integrin (MADCAM 1) 
interactions.17 Its inhibition of leukocyte trafficking is not 
organ specific. In addition to the gut, other organs such as 
brain, bone marrow and kidney are also affected. This had 
lead to studies in diverse chronic inflammatory conditions 
such as multiple sclerosis and Crohn’s disease.
Natalizumab efficacy 
in multiple sclerosis
Natalizumab is highly effective at preventing recurrent 
inflammation in patients with multiple sclerosis. The most 
striking effect is the reduction of contrast enhancing lesions 
on MRI and thus preventing clinical relapse. It is used in 
combination with interferon for treatment of relapsing and 
remitting multiple sclerosis.18
Clinical studies of natalizumab 
in Crohn’s disease
Natalizumab is an effective therapy for treatment of adults 
with moderately to severely active Crohn’s disease as 
defined by the Crohn’s Disease Activity Index (CDAI).19 
This conclusion is based on three randomized controlled 
trials.20,21 Two of these large randomized controlled trials 
were published together. The first was an induction trail 
entitled Efficacy of Natalizumab as Active Crohn’s Therapy 
(ENACT-1) and the second a maintenance trial entitled 
Evaluation of  Natalizumab as Continuous Therapy 
(ENACT-2). In the first study patients were randomized 
to 300 mg intravenous infusion of natalizumab or placebo 
at weeks 0, 4 and 8. The primary end point of this trial 
was clinical response as defined as a drop in the CDAI at 
week 10 of 70 points. Patients who responded were then 
eligible for the second study that randomized patients to 
300 mg intravenous natalizumab or placebo every 4 weeks 
through week 56. The primary outcome of this study was 
sustained response at week 36. ENACT-1 showed a slight 
statistical improvement in response with natalizumab 
compared to placebo at week 10 (56% vs 49%, P = 0.05) but 
this was not clinically meaningful and there was no difference 
in remission rates (37% vs 30%, P = 0.12). Continuing 
natalizumab as maintenance therapy among responders 
led to high response rates and remission rates compared to 
placebo (61 vs 28%: P  0.001 and 44 vs 26%; P = 0.003, 
respectively) at week 36. The minimal differences seen in 
ENACT-1 may have been due to patient selection since when 
the analysis was restricted to those with elevated C-reactive 
protein (indicating active disease) response and remission 
rates were higher. This led to a second study entitled Efficacy 
of Natalizumab in Crohn’s Disease Response and Remission 
(ENCORE) that randomized only patients with elevated 
C- reactive protein to natalizumab or placebo at weeks 0, 4 
and 8. Forty-eight percent of natalizumab treated patients 
had response at week 8 sustained to week 12 compared to 
32% for placebo (P  0.001) with remission rates 26% and 
16% respectively (P = 0.002). Overall response and remis-
sion rates were higher in the natalizumab groups compared 
to placebo at 0, 4 and 8 weeks. Corticosteroid tapering was 
more successful in the natalizumab group compared to the 
placebo group (58% vs 28%).
These studies support the efficacy of natalizumab for 
patients with moderately to severely active Crohn’s disease 
both for induction and maintenance of remission and are 
summarized in Figure 1. While response rates compared 
to other agents for Crohn’s disease were low, the patients 
enrolled in these studies differed in their disease severity 
and past medication usage. Over one-third of the patients in 
ENACT studies and half in the ENCORE studies previously 
had been exposed to antagonists to TNF and one-third in Therapeutics and Clinical Risk Management 2009:5 938
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both the studies received immunomodulator therapy during 
the trials. This suggests that these patients had more severe 
treatment refractory Crohn’s disease.
Both ENACT and ENCORE studies had other important 
limitations. These studies were primarily focused on non-
stricturing, non-penetrating disease and there is a lack of 
evidence for natalizumab in penetrating disease which is 
the primary limitation in application to the Crohn’s disease 
population. While TNF inhibitors have been proven to be 
effective in fistula healing and closure, there are no data on 
natalizumab.
In addition, the patient population studied was limited to 
those who had severe refractory disease and most of them had 
already been on treatment with immune modulators or tumor 
necrosis factor inhibitors. Like other trials, they excluded 
patients with an ostomy, short bowel or stricture. The studies 
also lacked power to detect serious adverse events. It is also 
important to understand that only adult patients were included 
in these studies. One trial to date focused on adolescents with 
Crohn’s disease and showed acceptable safety. Response 
rates were high but there was no placebo group.23 No study 
to date has shown any benefit of dosing based on patients 
weight or age. While C-reactive protein has not been shown 
to correlate well with disease severity in previous studies,24 in 
these natalizumab trials elevated levels did define a group of 
patients who were more likely to have a favorable response.
In the ENACT and ENCORE studies patients must not 
have received an antagonist to TNF for 3 months prior to 
study enrollment. In these trials patients who had previ-
ously received these agents were treatment failures. The 
question whether natalizumab can be administered with 
a TNF antagonist is potentially important. Clinicians may 
prefer to overlap therapy when a TNF antagonist is failing, 
to avoid severe disease exacerbations. The most important 
concern of this approach is safety. Short term safety and 
tolerability were confirmed among a population of patients 
receiving infliximab but not in remission who received 
natalizumab.25 However the study was small and improved 
therapeutic outcome could not be demonstrated and follow-
up was less than 1 year. This study was initiated before 
any cases of progressive multifocal leukoencephalopathy 
(PML) were reported in Crohn’s disease. This approach 
of overlapping TNF antagonist therapy with natalizumab 
can not be endorsed because of the short duration of this 
trial, its inability to detect rare important adverse events 
such as PML and concerns regarding significant immune 
suppression.
Positioning of natalizumab
Natalizumab has been approved for the treatment of mild 
to moderate Crohn’s disease with evidence of inflammation 
in the United States. Since its mode of action is completely 
different from other biological agents, it is an important 
option for the treatment of Crohn’s disease, among those 
patients who are intolerant or have lost efficacy to all other 
treatments including immune modulators and tumor necrosis 
factor inhibitors. Its restriction to use in these refractory 
cases is based on the risk of developing adverse events, 
particularly PML, which will be discussed further and current 
recommendation is that natalizumab should be administered 
as monotherapy (without concomitant immunosuppressive 
therapy) due to the risk of developing PML.
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Figure 1 Comparison of response and remission rates for three pivotal studies for natalizumab in moderate to severely active Crohn’s disease (P = 0.05 and P = 0.12 in 
ENACT-1, P  0.001 and P = 0.002 in ENCORE and P  0.001 and P = 0.003 in ENACT-2 for response and remission respectively).Therapeutics and Clinical Risk Management 2009:5 939
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Safety and adverse effects
The combined safety data for natalizumab in clinical studies 
suggest that the drug was generally well tolerated. Adverse 
events occurred infrequently and were experienced by a 
similar proportion of natalizumab and placebo-treated 
patients. There were no statistically significant differences 
in the proportions of patients who withdrew due to adverse 
events or those who experienced serious adverse events.
The most frequently reported adverse events with 
natalizumab infusion include headache, nausea, worsening 
of Crohn’s disease and nasopharyngitis. Other events 
include abdominal pain, arthralgias, fatigue, hypersensitivity 
like reactions and the development of antibodies against 
natalizumab. When persistent anti-natalizumab antibodies 
were present, they appear to be associated with infusion 
reactions and loss of efficacy. Antibodies to natalizumab 
were detected in 8% and 9% of natalizumab exposed patients 
in ENACT-1 and ENACT-2 trials respectively. During the 
ENACT-1 study, acute infusion reactions (any adverse event 
occurring within 120 minutes after the initiation of an infu-
sion) occurred in 8% of patients in the placebo group and 11% 
of those who received natalizumab. The corresponding rates 
for the ENACT-2 study were 8% and 7%. Hypersensitivity 
like reactions occurred in 2% of patients in the placebo group 
and 5% of those in the natalizumab group in ENACT-1 study. 
The corresponding rates were 1% and 3 % in the ENACT-2 
study. Acute infusion reactions included headache, urticaria 
and erythema. Although the incidence of acute infusion and 
hypersensitivity-like reactions was low, these events occurred 
more frequently among patients with persistent, but not 
transient antibodies against natalizumab. Concomitant use 
of immunosuppressive and corticosteroid therapy appeared 
to be moderately protective against antibody formation in 
both trials. There were no reported cases of lymphoma or 
tuberculosis during the studies.
Progressive multifocal 
leukoencephalopathy (PML)
PML is an opportunistic infection of the central nervous 
system caused by Jacob-Creutzfeldt (JC) polyoma virus 
which results in multiple foci of demyelination in the white 
matter and cerebral cortex, leading to severe and potentially 
fatal neurological dysfunction.26 Clinical symptoms include 
weakness or paralysis, vision loss, impaired speech, cognitive 
impairment and depending on the area of involvement a 
plethora of neurological symptoms and signs can manifest. 
The virus attacks the oligodendrocytes in the central nervous 
system which produce myelin and hence it progresses rapidly 
often leading to death. It is diagnosed by testing for JC 
virus DNA in the cerebrospinal fluid or in a brain biopsy 
specimen.
The classic histopathological hallmarks of PML include 
enlarged oligodendroglial nuclei at the border of areas of 
demyelination, giant, bizarre astrocytes and lipid laden 
macrophages that scavenge myelin debris. In situ hybridiza-
tion or immuno-histochemical staining permits identification 
of the virus. Characteristic evidence of damage caused by the 
virus in the brain can also be detected by magnetic resonance 
imaging. PML almost invariably occurs in the setting of 
profoundly impaired cell mediated immunity in patients 
with AIDS, leukemia or in organ transplant recipients. 
There is no known cure or definitive therapy available for 
PML. AIDS patients treated with highly active anti retroviral 
therapy (HAART) after being diagnosed with PML tend to 
have a slightly longer survival time than in patients who 
were already on HAART and then developed PML.27 Other 
antiviral agents that have been studied as possible treatment 
options include cidofovir and interleukin-2 but the research 
is still preliminary.
The occurrence of PML in patients with Multiple Sclerosis 
and Crohn’s disease treated with natalizumab was totally 
unexpected. Three patients out of 3000 who had participated 
in clinical trials of natalizumab for treatment of multiple 
sclerosis or Crohn’s disease developed PML.28 The first case 
was a 23-year-old male with relapsing-remitting multiple 
sclerosis diagnosed in 1997, on treatment with interferon 
beta since 1998 was enrolled in a double blind trial of natali-
zumab and interferon beta in 2002. The patient developed 
inappropriate behavior in November 2004 and eventually 
progressed to left hemiparesis, dysarthria and cognitive 
impairment. After receiving 28 infusions of natalizumab the 
last dose in December 2004 the patient stopped the study 
drug. He was not immune compromised and had no risk 
factors for HIV . Analysis of cerebrospinal fluid resulted in JC 
virus DNA detection and diagnosis of PML was confirmed by 
brain biopsy. He was treated with intravenous cidofovir with 
further worsening of neurological function following which 
intravenous cytarabine was initiated resulting in neurological 
improvement in 2 weeks. By the end of May 2005 he had 
improved motor and cognitive function but he still had 
disabling ataxia, cognitive impairment, mild neglect and left 
hemiparesis at the time of his most recent follow-up.29
A 46-year-old woman with relapsing-remitting multiple 
sclerosis died from PML after receiving 37 doses of natali-
zumab as part of a clinical trial in combination with interferon Therapeutics and Clinical Risk Management 2009:5 940
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beta in 2005. She developed sensory motor deficits and 
cognitive impairment that progressed rapidly and was treated 
with pulsed solumedrol assuming that she had multiple 
sclerosis exacerbation. After extensive investigations the 
treating neurologist suspected PML and a CSF analysis for 
JC virus PCR was positive. This patient did not receive any 
definitive treatment for PML.30 A sixty year old patient with 
long-standing ileal Crohn’s disease treated with natalizumab 
in March 2002 as part of the ENACT-1 trial presented to the 
emergency room in July 2003 with severe confusion and 
disorientation. He had received 3 monthly infusions of 300 mg 
of  natalizumab and then resumed in February 2003 for a 
relapse of Crohn’s disease. He had been treated with multiple 
therapies including azathioprine (75 to 150 mg) which was 
discontinued 8 months before this presentation due to refrac-
tory anemia. This patient had no focal neurological signs at 
presentation except for being mentally slow. His brain MRI 
revealed non enhancing lesions in the right frontal lobe. 
Because of progressive deterioration in his condition a partial 
resection of right frontal lobe was performed and a diagno-
sis of astrocytoma was entertained based on pathological 
findings. The patient’s condition worsened post operatively 
and treatment with corticosteroids was initiated. He continued 
to deteriorate rapidly and died 3 months later in December 
2003. In March 2005 after the occurrence of PML in two 
patients with multiple sclerosis who had received natalizumab, 
this patient’s course was re-examined. Examination of the 
formalin fixed tissue from the resected brain lesions confirmed 
the diagnosis of PML.31 A clear temporal relationship was 
identified between the monthly natalizumab infusions 
and the occurrence of JC virus replication. Although he 
had been treated with corticosteroids, infliximab and 
azathioprine, JC virus DNA appeared in the serum only after 
the re-introduction of natalizumab as monotherapy.31 The 
three cases confirm that PML is a rapidly progressive and 
potentially fatal disease associated with natalizumab usage. 
Similarities among the patients include the clinical presenta-
tion and the speed in progression of clinical symptoms and 
signs. All three patients were concomitantly receiving other 
immunosuppressive agents preceding the diagnosis of PML. 
A retrospective study conducted by Yousry et al of more than 
3000 patients who received natalizumab for multiple sclerosis, 
Crohn’s disease and rheumatoid arthritis found no new case of 
PML and suggested a risk of developing the disease is about 
one per thousand patients (0.2 to 2.8 per thousand) treated 
with natalizumab for a mean duration of 18 months.32
The exact pathogenesis for the development of PML in the 
setting of natalizumab therapy is still unclear. One hypothesis 
defended by some authors that PML occurs as a result of 
viral re-activation from within the brain and do not support 
the suggestion that JC virus is activated from its latent stage 
in the kidneys, to enter the blood and then seed the central 
nervous system which is the basis of hypothesis by Verbeeck 
and colleagues.33
Identification of reliable predictors for PML risk remains 
a high currently unmet need to improve the safety of 
natalizumab. There is no clear evidence that screening for 
JC virus in urine and plasma could improve the safety.34 
Early detection of the disease and prompt removal of the 
drug should remain the goal of treating clinicians. The most 
reliable biomarker of PML short of brain biopsy is detection 
of JC virus DNA in the cerebrospinal fluid of infected 
patients. While this has a high specificity, sensitivity is 
modest, being undetectable in 10% to 40% of patients with 
active disease, with no evidence that it could be used as a 
predictive marker.35,36 The only other sensitive test is a brain 
MRI which virtually detects all clinical lesions. However 
PML is an aggressive disease and detection in the asymp-
tomatic stage has rarely if ever been reported presumably 
because it becomes clinically manifest rapidly, often leading 
to death within a few months.37
Since reversal of immune system is key to the arrest of 
PML, early withdrawal of the drug and possible acceleration 
of drug elimination through plasma exchange38 may minimize 
harm. Patients must understand and accept the rare risk of 
disability or death from PML, as opposed to the burden of 
Crohn’s disease when the decision to use natalizumab is 
entertained. The benefit is more likely to outweigh the risk 
among a population with Crohn’s disease who have failed 
immunomodulator therapy and biological therapies who are 
either poor candidates or have refused surgery.
Drug administration issues
Natalizumab is only available through a special restricted 
distribution program called the “TOUCH” prescribing 
program. (Tysabri Outreach: Unified Commitment to 
Health).39 This was developed by the manufacturer, Elan, 
because of the risk of Progressive Multifocal leukoencepha-
lopathy (PML). This program restricts the use of natalizumab 
to patients with refractory disease and those who have failed 
treatment or developed intolerance to immune modulators 
and or tumor necrosis factor inhibitors.
The primary goal of the “TOUCH” program is to 
minimize the risk of developing PML. Prescribers and their 
patients who are to receive this medication must be enrolled 
in the program. Pharmacies who supply and infusion sites Therapeutics and Clinical Risk Management 2009:5 941
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that administer the medication must also be authorized 
by the program. The program offers more interaction for 
the patients with their treating doctors and nurses. Before 
each infusion four questions (Table 2) are read aloud and 
answered verbally by the recipient. These questions assist in 
identifying patients at higher risk of developing PML while 
on treatment with natalizumab through inquires about new 
neurological symptoms, co-existing illness (HIV, AIDS, 
leukemia, lymphoma, organ transplant) and the use of other 
immune suppressive medications. If any potential risk of 
the infusion is identified the site staff must contact the 
patients healthcare professional prior to proceeding with the 
infusion.39 Natalizumab is usually administered as an intrave-
nous infusion of 300 mg over a period of 1 hour, every 4 weeks 
in an authorized infusion center. It should not be administered 
as an intravenous push or bolus. Patients are observed during 
the infusion and for 1 hour after the infusion is complete due 
to the risk of acute infusion reactions. It should be discontin-
ued in patients with Crohn’s disease if therapeutic benefit has 
not been achieved by 12 weeks of induction therapy and also 
in patients who are unable to discontinue concomitant steroid 
use within 6 months of starting therapy with natalizumab.
Cost
Currently the approximate cost of natalizumab is US$2,184 
per vial for an annual cost of approximately US$28,400.40
Conclusion
Crohn’s disease is a chronic potentially disabling disease 
of the gastrointestinal system that is neither medically nor 
surgically curable. The treatment goals primarily revolve 
around induction and maintenance of remission, improvement 
of quality of life and minimizing long-term complications. 
Newer biologic therapies have been shown to be highly 
effective and are likely to be used earlier in the disease course 
to improve prognosis.
Natalizumab is a novel agent that selectively inhibits 
leukocyte trafficking. It is approved for the treatment of 
moderate to severe non-stricturing, non-penetrating Crohn’s 
disease. Its efficacy is supported by rigorous clinical trials. 
Its use is currently limited to patients who have not tolerated 
or failed treatment with other biological agents (antibodies 
to tumor necrosis factor). Its effectiveness in anti-TNF naïve 
patients is not known but there is little enthusiasm for study 
in this population since anti-TNF agents are effective and 
well tolerated. Natalizumab should not be used concomitantly 
with other immunological agents due to the potential but rare 
risk of developing PML. It is currently only available through 
a special restricted program called “TOUCH” for patients 
with Crohn’s disease. Due to the lack of reliable markers for 
predicting the risk of PML, future research should identify 
patients who are most likely to benefit from natalizumab 
therapy, while minimizing the possibility of rare but serious 
adverse events and also in developing reliable markers for 
predicting these events.
The development of natalizumab has lead to preliminary 
testing of a humanized anti-alpha4 beta7 integrin antibody 
(vedolizumab) which inhibits gut specific MADCAM 1 
mediated leukocyte adhesion. This agent is currently being 
developed only for the treatment of Crohn’s disease and 
ulcerative colitis.41 If effective and safe these gut-specific 
therapies will be tested as primary options and would expand 
the available treatment options for Crohn’s disease.
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